Patients, n | 15 |
Demographics | |
Age (years) | |
Mean±SD (N) | 54.65±8.87 (15) |
Median, range (min, max) | 58.70, (37.00, 65.00) |
(95% CI) | (49.74 to 59.56) |
Gender | |
Male | 40.00% (6/15) |
Female | 60.00% (9/15) |
BCVA ETDRS letters at baseline | |
Mean±SD (N) | 82.47±8.05 (30) |
Median, range (min, max) | 84.00, (51.00, 93.00) |
(95% CI) | (79.46 to 85.47) |
Duration of diagnosis before the trial (months) | |
Mean±SD (N) | 25.60±34.73 (15) |
Median, range (min, max) | 12.00, (2.00, 120.00) |
(95% CI) | (6.37 to 44.83) |
Treated with corticosteroids before the trial | 80.00% (12/15) |
How long were corticosteroids stopped before the trial? (months) | |
Mean±SD (N) | 18.17±35.48 (12) |
Median, range (min, max) | 1.00, (0.00, 116.00) |
High-dose corticosteroids within 6 months before enrolment* | 26.67% (4/15) |
Corticosteroids-sparing drugs before the trial | |
Any corticosteroid-sparing treatment | 73.33% (11/15) |
Duration of corticosteroid-sparing treatment (months) | |
Mean±SD (N) | 25.73±34.31 (11) |
Median, range (min, max) | 13.00, (1.00, 120.00) |
Cyclosporine A | 63.64% (7/11) |
Mycophenolate mofetil | 27.27% (3/11) |
Sirolimus | 9.09% (1/11) |
Methotrexate | 27.27% (3/11) |
*Equivalent of prednisolone 1 mg/kg and/or periocular or intravitreal corticosteroid injection.
BCVA, best corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.